present invention relates to a method for determining a patient with heart failure are likely to respond to statin-containing therapy. The method, in a sample from a patient, GDF-15 (growth differentiation factor 15), urea, SHBG (sex hormone binding globulin), uric acid, PLGF (placental growth factor), IL-6 (interleukin-6), transferrin, heart troponin, sFlt-1 (soluble fms- like tyrosine kinase-1), prealbumin, ferritin, osteopontin, SST2 (soluble ST 2), and hsCRP least one member selected from (high-sensitivity C- reactive protein) It is based on measuring the level of the marker. Method of predicting the risk of a patient afflicted with death or hospitalization, are further contemplated, wherein the patient has undergone and statin-containing therapy have heart failure. The method is also based on measurement of at least one level above the markerBACKGROUND
